Hexagon Bio closed a $62 million Series C to fund the first-in-human HEX-360 study and advance its antibody-drug conjugate platform.
- Amount
- $62M
- Stage
- Series C
- Announced
- 23 October 2026
- Lead
- The Column Group
- Other investors
- Nextech Invest, Deviation Capital, 8VC, Canada Pension Plan Investment Board (CPP Investments)
- Use of funds
- Supports Phase 1 trial of HEX-360 and advances additional novel payload mechanisms and dual payloads from platform.
- Checked
- Announced by the company